Sartorius Stedim Biotech and Repligen collaborate to create novel perfusion-enabled bioreactors

Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, and Repligen Corporation, a global life sciences company focused on bioprocessing technologies, have entered into a collaboration agreement to integrate Repligen’s XCell ATF cell retention control technology into SSB’s BIOSTAT® STR large-scale single-use bioreactors to create novel perfusion-enabled bioreactors. As a result of this collaboration, end users will stand to benefit from a single control system for 50 L to 2,000 L bioreactors used in perfusion cell culture applications. This single interface is designed to control cell growth, fluid management and cell retention in continuous and intensified bioprocessing and, ultimately, simplify the development and cGMP manufacture of biological drugs.

For perfusion cell culture application Repligen’s XCell ATF cell retention control technology will be integrated into SSB’s BIOSTAT® STR large-scale single-use bioreactors

Through the partnership, Sartorius Stedim Biotech and Repligen will further collaborate to equip SSB’s recently launched ambr® 250ht perfusion single-use mini bioreactor system with Repligen’s KrosFlo® hollow fiber filter technology. The bioreactor system will be sold by SSB as a complete single-use assembly. This optimal design conserves hollow fiber filter technology across scales, enabling customers to fast track development and scale up their cell culture perfusion processes.

“Sartorius Stedim Biotech has continuously expanded its integrated upstream portfolio over the past years with a focus on robust and scalable, automated single-use solutions, optimized for high-cell-density applications. The collaboration with Repligen will result in easy-to-implement, high-performance and perfusion-ready bioreactors ranging from process development to commercial manufacturing scale,” commented Stefan Schlack, Head of Marketing at SSB.

Christine Gebski, Vice President of Product Management at Repligen, stated:

We are excited to partner with Sartorius Stedim Biotech, a global innovator in bioreactor technology. The integration of our market-leading XCell ATF control technology with SSB’s high-performance bioreactors offers a simplified perfusion-enabled bioreactor solution for end users to develop cell culture processes more quickly and implement perfusion more efficiently.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sartorius. (2019, June 20). Sartorius Stedim Biotech and Repligen collaborate to create novel perfusion-enabled bioreactors. News-Medical. Retrieved on May 24, 2024 from https://www.news-medical.net/news/20180905/Sartorius-Stedim-Biotech-and-Repligen-collaborate-to-create-novel-perfusion-enabled-bioreactors.aspx.

  • MLA

    Sartorius. "Sartorius Stedim Biotech and Repligen collaborate to create novel perfusion-enabled bioreactors". News-Medical. 24 May 2024. <https://www.news-medical.net/news/20180905/Sartorius-Stedim-Biotech-and-Repligen-collaborate-to-create-novel-perfusion-enabled-bioreactors.aspx>.

  • Chicago

    Sartorius. "Sartorius Stedim Biotech and Repligen collaborate to create novel perfusion-enabled bioreactors". News-Medical. https://www.news-medical.net/news/20180905/Sartorius-Stedim-Biotech-and-Repligen-collaborate-to-create-novel-perfusion-enabled-bioreactors.aspx. (accessed May 24, 2024).

  • Harvard

    Sartorius. 2019. Sartorius Stedim Biotech and Repligen collaborate to create novel perfusion-enabled bioreactors. News-Medical, viewed 24 May 2024, https://www.news-medical.net/news/20180905/Sartorius-Stedim-Biotech-and-Repligen-collaborate-to-create-novel-perfusion-enabled-bioreactors.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Sartorius strengthens its bioanalytics portfolio by acquiring a majority stake in ALS Automated Lab Solutions